MARKET

SLS

SLS

SELLAS LIFE SCIE
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.720
+0.170
+4.79%
Closed 16:00 11/27 EST
OPEN
3.590
PREV CLOSE
3.550
HIGH
3.800
LOW
3.590
VOLUME
216.66K
TURNOVER
--
52 WEEK HIGH
4.890
52 WEEK LOW
1.455
MARKET CAP
35.20M
P/E (TTM)
-1.0967
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
SELLAS Life Sciences Q3 EPS $(0.53) Up From $(2.68) YoY
SELLAS Life Sciences (NASDAQ:SLS) reported quarterly losses of $(0.53) per share. This is a 80.22 percent increase over losses of $(2.68) per share from the same period last year.
Benzinga · 11/13 21:35
5 Value Stocks To Watch In The Healthcare Sector
What are Value Stocks? A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators that the company is undervalued and can most likely be labeled as a value stock.Below is a list of notable value stocks in the healthcare sector: 1. SELLAS Life Sciences Gr (NASDAQ: SLS) - P/E: 0.62 2. Supernus Pharmaceuticals (NASDAQ: SUPN) - P/E: 9.78 3. Ocugen (NASDAQ: OCGN) - P/E: 0.04 4. Oncternal Therapeutics (NASDAQ: ONCT) - P/E: 4.61 5. Coherus BioSciences (NASDAQ: CHRS) - P/E: 7.01SELLAS Life Sciences Gr has been featured as a value stock. SELLAS Life Sciences Gr's Q2 EPS sits at -0.66, which has not changed since last quarter (Q1). SELLAS Life Sciences Gr does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.Most recently, Supernus Pharmaceuticals reported earnings per share at 0.74, whereas in Q2 earnings per share sat at 0.65. Supernus Pharmaceuticals does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.Ocugen has reported Q3 earnings per share at -0.02, which has increased by 89.47% compared to Q2, which was -0.19. Ocugen does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.Most recently, Oncternal Therapeutics reported earnings per share at -0.22, whereas in Q2 earnings per share sat at -0.34. Oncternal Therapeutics does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.Coherus BioSciences's earnings per share for Q3 sits at 0.47, whereas in Q2, they were at 0.81. Coherus BioSciences does not have a dividend yield, which investors should be aware of when considering holding onto such a stock.These 5 value stocks were selected by Benzinga Insights based on quantified analysis. While this methodical judgment process is not meant to make final decisions, our technology can give investors additional perception into the sector.See more from Benzinga * Click here for options trades from Benzinga * 5 Value Stocks To Watch In The Real Estate Sector * Return On Capital Employed Overview: Pfizer(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga · 11/09 14:30
SELLAS Reports Receives Investigational Medicinal Product Dossier Approval From French Regulatory Authority, Agence Nationale de Sécurité du Médicament et des Produits de Santé, To Advance Pivotal Phase 3 REGAL Study
SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad
Benzinga · 09/09 12:31
SELLAS Receives IMPD Approval from the French Regulatory Authority for its Pivotal Phase 3 REGAL Study of Galinpepimut-S in Patients with Acute Myeloid Leukemia
NEW YORK, Sept. 09, 2020 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications, today announced that it has received
GlobeNewswire · 09/09 12:30
Healthcare - Top 5 Gainers / Losers
Gainers: Midatech Pharma MTP +71%. Mesoblast MESO +45%. Taiwan Liposome TLC +40%. Kamada (KMDA) +14%. BioDelivery Sciences International (BDSI) +14%.Losers: Biofrontera BFRA -24%. Co-Diagnostics CODX -23%. OptiNose OPTN -23%. Equillium  EQ -20%. SELLAS Life Sciences (SLS) -12%.
Seekingalpha · 08/14 15:00
SELLAS Life Sciences Provides Business Update and Reports Second Quarter 2020 Financial Results
GlobeNewswire · 08/13 21:30
SELLAS Life Sciences EPS misses by $0.02
SELLAS Life Sciences (SLS): Q2 GAAP EPS of -$0.66 misses by $0.02.Cash of $3.3M at end of Q2. The company raised $9.2M in gross proceeds in August.Press Release
Seekingalpha · 08/13 20:43
SELLAS Life Sciences EPS misses by $0.02
SELLAS Life Sciences (SLS): Q2 GAAP EPS of -$0.66 misses by $0.02.Cash of $3.3M at end of Q2. The company raised $9.2M in gross proceeds in August.Press Release
Seekingalpha · 08/13 20:43
More
Forecast
EPSBVPSCFPS
Actual (K USD)
Estimate (K USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of SLS. Analyze the recent business situations of SELLAS LIFE SCIE through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average SLS stock price target is 8.00 with a high estimate of 8.00 and a low estimate of 8.00.
EPS
Institutional Holdings
Institutions: 39
Institutional Holdings: 9.48M
% Owned: 100.22%
Shares Outstanding: 9.46M
TypeInstitutionsShares
Increased
3
3.81K
New
7
215.77K
Decreased
3
25.50K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.18%
Pharmaceuticals & Medical Research
+1.72%
Key Executives
Chairman/Independent Director
Jane Wasman
President/Chief Executive Officer/Director
Angelos Stergiou
Executive Vice President/General Counsel/Secretary
Barbara Wood
Senior Vice President
Dragan Cicic
Chief Accounting Officer/Vice President - Finance/Controller
John Burns
Director
David Scheinberg
Independent Director
Robert Van Nostrand
Independent Director
Stephen Ghiglieri
Independent Director
John Varian
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About SLS
SELLAS Life Sciences Group, Inc., formerly Galena Biopharma, Inc., is a biopharmaceutical company. The Company focuses on developing and commercializing targeted oncology therapeutics that address unmet medical needs. The Company's development portfolio ranges from mid- to late-stage clinical assets, including cancer immunotherapy program led by NeuVax (nelipepimut-S), GALE-301 and GALE-302. The Company's NeuVax is in Phase III breast cancer clinical trial with several concurrent Phase II trials ongoing both as a single agent and in combination with other therapies. GALE-301 is in a Phase IIa clinical trial in ovarian and endometrial cancers and in a Phase Ib clinical trial given sequentially with GALE-302. The Company's therapies utilize an immunodominant peptide combined with the immune adjuvant, recombinant human granulocyte macrophage-colony stimulating factor (rhGM-CSF, Leukine), and work by harnessing the patient's own immune system.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Sellas Life Sciences Group Inc stock information, including NASDAQ:SLS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SLS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SLS stock methods without spending real money on the virtual paper trading platform.